Skip to main content
Top
Published in: Rheumatology International 9/2016

Open Access 01-09-2016 | Epidemiology of RMD

Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland

Authors: Paweł Kawalec, Krzysztof Piotr Malinowski, Andrzej Pilc

Published in: Rheumatology International | Issue 9/2016

Login to get access

Abstract

The aim of the study was to assess the indirect costs, health-related quality of life and clinical characteristics of patients with psoriatic arthritis (PsA), measured using a PsA disease activity index in Poland. Additionally, we aimed to investigate the association between the activity, utility of PsA-affected patients and productivity loss in a Polish setting. A questionnaire survey was conducted to assess disease activity, as well as productivity loss, and a paper version of the EuroQoly-5D-3L questionnaire was used to assess productivity loss and the quality of life. Indirect costs were assessed with the human capital approach employing the gross domestic product (GDP) per capita, gross value added (GVA) and gross income (GI) per worker in 2014 in Poland and were expressed in Polish zlotys (PLN) as well as in euros. The correlation was presented using the Spearman correlation coefficient. Our analysis was performed on the basis of 50 full questionnaires collected. We observed a mean utility value of 0.6567. The mean number of days off work was 2.88 days per month, and mean on-the-job productivity loss was 24.1 %. Average monthly indirect costs per patient were €206.7 (864.01 PLN) calculated using the GDP; €484.56 (2025.46 PLN) calculated using the GVA; and €209.70 (876.56 PLN) calculated using the GI. PsA reduces the patients’ quality of life as well as their productivity loss associated with both absenteeism and presenteeism. Total indirect costs were negatively correlated with utility. The greater the disease activity, the lower the utility and the greater the indirect costs.
Literature
1.
go back to reference Puig L, Fan T, Ding Q, Smith NE (2014) Predictors of biologic treatment of psoriasis: a non-interventional study. ClinicoEcono Outcomes Res 6:93–100 Puig L, Fan T, Ding Q, Smith NE (2014) Predictors of biologic treatment of psoriasis: a non-interventional study. ClinicoEcono Outcomes Res 6:93–100
3.
go back to reference Sørensen J, Hetland ML (2015) Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74(3):e12CrossRefPubMed Sørensen J, Hetland ML (2015) Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74(3):e12CrossRefPubMed
7.
go back to reference Szende A, Oppe M, Devlin N (eds) (2007) EuroQol 5 value sets: inventory, comparative review, and user guide. Springer, Netherlands Szende A, Oppe M, Devlin N (eds) (2007) EuroQol 5 value sets: inventory, comparative review, and user guide. Springer, Netherlands
11.
go back to reference Kawalec P, Malinowski KP (2015) The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 15:125–132CrossRefPubMed Kawalec P, Malinowski KP (2015) The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 15:125–132CrossRefPubMed
12.
go back to reference Moreno JC, Daudén E, Rodriguez-Valverde V, Gomez-Reino J, Gratacos J, Sabater FJ, Casado MA (2009) A cost-of-illness study of psoriatic arthritis in Spain. Value Health 12:7 (Abstract) CrossRef Moreno JC, Daudén E, Rodriguez-Valverde V, Gomez-Reino J, Gratacos J, Sabater FJ, Casado MA (2009) A cost-of-illness study of psoriatic arthritis in Spain. Value Health 12:7 (Abstract) CrossRef
13.
go back to reference Brodszky V, Becsi R, Karpati K, Pentek M, Sebestyen A, Boncz I et al (2009) Costs of psoriatic arthritis in Hungary; results from a cross-sectional survey. Value Health 12:3 (Abstract) Brodszky V, Becsi R, Karpati K, Pentek M, Sebestyen A, Boncz I et al (2009) Costs of psoriatic arthritis in Hungary; results from a cross-sectional survey. Value Health 12:3 (Abstract)
14.
go back to reference Brodszky V, Bálint P, Géher P, Hodinka L, Horváth G, Koó É et al (2009) Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 30:199–205CrossRefPubMed Brodszky V, Bálint P, Géher P, Hodinka L, Horváth G, Koó É et al (2009) Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 30:199–205CrossRefPubMed
15.
go back to reference Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65:1175–1183CrossRefPubMedPubMedCentral Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65:1175–1183CrossRefPubMedPubMedCentral
16.
go back to reference Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Apadaro A et al (2008) The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients within adequate response to conventional therapy. Rheumatology 47:1664–1670CrossRefPubMedPubMedCentral Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Apadaro A et al (2008) The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients within adequate response to conventional therapy. Rheumatology 47:1664–1670CrossRefPubMedPubMedCentral
17.
go back to reference Klimes J, Dolezal T (2010) Indirect costs of moderate and severe forms of psoriasis in Czech Republic: calculation based on self reported questionnaire. Value Health. doi:10.1016/S1098-3015(11)72995-3 Klimes J, Dolezal T (2010) Indirect costs of moderate and severe forms of psoriasis in Czech Republic: calculation based on self reported questionnaire. Value Health. doi:10.​1016/​S1098-3015(11)72995-3
18.
go back to reference Kvamme MK, Lie E, Kvien TK, Kristiansen IS (2012) Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology 51:1618–1627CrossRefPubMed Kvamme MK, Lie E, Kvien TK, Kristiansen IS (2012) Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology 51:1618–1627CrossRefPubMed
19.
go back to reference Zhu TY, Tam LS, Leung YY, Kwok LW, Wong KC, Yu T et al (2010) Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 37:1214–1220CrossRefPubMed Zhu TY, Tam LS, Leung YY, Kwok LW, Wong KC, Yu T et al (2010) Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 37:1214–1220CrossRefPubMed
Metadata
Title
Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland
Authors
Paweł Kawalec
Krzysztof Piotr Malinowski
Andrzej Pilc
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3514-3

Other articles of this Issue 9/2016

Rheumatology International 9/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.